Table 4.

Patients with 6MSF (N = 131) vs 6MNSF (N = 73) as a prognostic factor.

	6MSF, N (%)	6MNSF, N (%)	p-Value	OR	95% CI
Gender
Women	48 (36.6)	32 (43.8)	0.313	0.741	0.414–1.328
Men	83 (63.4)	41 (56.2)
Age at seizure onset (years)
≤16	75 (57.3)	40 (54.8)	0.734	1.105	0.621–1.966
>16	56 (42.7)	33 (45.2)
Number of seizures before treatment
1–9 times	114 (87.0)	52 (71.2)	0.005*	2.708	1.320–5.556
≥10 times	17 (13.0)	21 (28.8)
Pretreatment duration (months)
<6	58 (44.3)	39 (53.4)	0.210	0.693	0.390–1.231
≥6	73 (55.7)	34 (46.6)
Seizure type
Partial	98 (74.8)	59 (80.8)	0.328	0.705	0.349–1.424
Generalized	33 (25.2)	14 (19.2)
Epilepsy etiology
Idiopathic	47 (35.9)	27 (37.0)	0.875	0.953	0.526–1.727
Symptomatic	84 (64.1)	46 (63.0)
MRI or CT record at entry
Normal	92 (70.2)	40 (54.8)	0.027*	1.946	1.075–3.525
Abnormal	39 (29.8)	33 (45.2)
EEG at entry
Normal	26 (19.8)	13 (17.8)	0.723	1.143	0.547–2.389
Abnormal	105 (80.2)	60 (82.2)
Family history
No	126 (96.2)	69 (94.5)	0.579	1.461	0.380–5.619
Yes	5 (3.8)	4 (5.5)
History of febrile seizure
No	119 (90.8)	69 (94.5)	0.349	0.575	0.178–1.852
Yes	12 (9.2)	4 (5.5)

6MSF, patients who were seizure-free over the initial 6 months; 6MNSF, patients who were not seizure-free over the initial 6 months; EEG, electroencephalography; MRI, magnetic resonance imaging; CT, computed tomography; OR, odds ratio; CI, confidence interval.

*p-Values obtained from chi-square tests with significant statistical differences.